Dmitriy Stasishin, DO
Endocrinology, Diabetes & Metabolism · Falls Church, VANPI 1548723281
Payments from drug & device makers
Across 129 payments — averaging $24.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$386
- Xeris Pharmaceuticals, Inc.$303
- Lilly USA, LLC$274
- Sanofi-aventis U.S. LLC$201
- Boehringer Ingelheim$185
- Madrigal Pharmaceuticals$177
- plus $2K from 28 others
What the payments were for
- Food & beverage$3,12299%
- Education$431%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $386 |
| Xeris Pharmaceuticals, Inc. | 13 | $303 |
| Lilly USA, LLC | 14 | $274 |
| Sanofi-aventis U.S. LLC | 8 | $201 |
| Boehringer Ingelheim | 9 | $185 |
| Madrigal Pharmaceuticals | 3 | $177 |
| Radius Health, Inc. | 5 | $169 |
| Corcept Therapeutics | 7 | $160 |
| Antares Pharma, Inc. | 6 | $155 |
| Sequel Med Tech, LLC | 2 | $148 |
| Dexcom, Inc. | 4 | $105 |
| Amgen | 4 | $82 |
| Insulet Corporation | 3 | $71 |
| Mannkind Corporation | 3 | $71 |
| AstraZeneca | 3 | $64 |
| AbbVie | 4 | $58 |
| Abbott | 2 | $54 |
| Recordati_rare_diseases_inc. | 3 | $52 |
| Bayer | 2 | $50 |
| BETA Bionics, Inc. | 2 | $48 |
| Neurocrine Biosciences, Inc. | 2 | $48 |
| Kyowa Kirin, Inc. | 2 | $43 |
| Astellas Pharma US Inc | 2 | $36 |
| Globus Medical | 1 | $34 |
| Tandem Diabetes Care, Inc. | 1 | $31 |
| Pfizer | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Amneal Pharmaceuticals LLC | 1 | $18 |
| Medtronic | 1 | $18 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Nevro Corp. | 1 | $16 |
| Cequr Corporation | 1 | $16 |
| Rhythm Pharmaceuticals, Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,165 in reported general payments places this provider in the 60th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
See all endocrinology, diabetes & metabolism providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 33 | $70,244 |
| MounjaroTirzepatide | 31 | $56,431 |
| JardianceEmpagliflozin | 23 | $32,689 |
| TrulicityDulaglutide | 18 | $24,401 |
| Humalog Kwikpen U-100Insulin Lispro | 13 | $3,158 |
| SynthroidLevothyroxine Sodium | 19 | $1,922 |
| Hydrocortisone | 27 | $1,543 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 13 | $1,511 |
| Levothyroxine Sodium | 48 | $478 |
| Methimazole | 24 | $226 |
| Metformin Hcl ErMetformin Hcl | 13 | $217 |
| Metformin Hcl | 17 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $274 | $80,83249 claims |
| Novo NordiskOzempic | $386 | $70,24433 claims |
| Boehringer IngelheimJardiance | $185 | $32,68923 claims |
| AbbVieSynthroid | $58 | $1,92219 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $18 | $47848 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 223 endocrinology, diabetes & metabolism providers in Virginia.
Other endocrinology, diabetes & metabolism in Falls Church
- Stephen ClementFalls Church$60K
- Pedram JavanmardFalls Church$6K
- Firoozeh ShahidiFalls Church$5K
- Domenica RubinoArlington$3M
- Suzanne Jan de BeurCharlottesville$1.5M
- Farhad ZangenehSterling$1.2M
- Ali IranmaneshSalem$1.1M
- Elias SirajNorfolk$884K
- James MulindaRoanoke$788K
- Jeffrey SicatGlen Allen$657K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.